Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.

Quotti Tubi L, Gurrieri C, Brancalion A, Bonaldi L, Bertorelle R, Manni S, Pavan L, Lessi F, Zambello R, Trentin L, Adami F, Ruzzene M, Pinna LA, Semenzato G, Piazza F.

J Hematol Oncol. 2013 Oct 12;6:78. doi: 10.1186/1756-8722-6-78.

2.

Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.

Manni S, Brancalion A, Mandato E, Tubi LQ, Colpo A, Pizzi M, Cappellesso R, Zaffino F, Di Maggio SA, Cabrelle A, Marino F, Zambello R, Trentin L, Adami F, Gurrieri C, Semenzato G, Piazza F.

PLoS One. 2013 Sep 27;8(9):e75280. doi: 10.1371/journal.pone.0075280. eCollection 2013.

3.
4.

p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2.

Schneider CC, Hessenauer A, Montenarh M, Götz C.

Prostate. 2010 Feb 1;70(2):126-34. doi: 10.1002/pros.21044.

PMID:
19760628
5.

Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.

Rao J, Xu DR, Zheng FM, Long ZJ, Huang SS, Wu X, Zhou WH, Huang RW, Liu Q.

J Transl Med. 2011 May 19;9:71. doi: 10.1186/1479-5876-9-71.

6.

Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.

Borgo C, Cesaro L, Salizzato V, Ruzzene M, Massimino ML, Pinna LA, Donella-Deana A.

Mol Oncol. 2013 Dec;7(6):1103-15. doi: 10.1016/j.molonc.2013.08.006. Epub 2013 Aug 22.

7.

Pleiotropic effects of spongean alkaloids on mechanisms of cell death, cell cycle progression and DNA damage response (DDR) of acute myeloid leukemia (AML) cells.

Stuhldreier F, Kassel S, Schumacher L, Wesselborg S, Proksch P, Fritz G.

Cancer Lett. 2015 May 28;361(1):39-48. doi: 10.1016/j.canlet.2015.02.030. Epub 2015 Feb 16.

PMID:
25697484
8.

Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.

Zanin S, Borgo C, Girardi C, O'Brien SE, Miyata Y, Pinna LA, Donella-Deana A, Ruzzene M.

PLoS One. 2012;7(11):e49193. doi: 10.1371/journal.pone.0049193. Epub 2012 Nov 8.

9.

Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.

Pizzi M, Piazza F, Agostinelli C, Fuligni F, Benvenuti P, Mandato E, Casellato A, Rugge M, Semenzato G, Pileri SA.

Oncotarget. 2015 Mar 30;6(9):6544-52.

10.

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C, Proffitt C, Schwaebe MK, Ryckman DM, Rice WG, Anderes K.

Cancer Res. 2010 Dec 15;70(24):10288-98. doi: 10.1158/0008-5472.CAN-10-1893.

11.

siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53.

Liu H, Wang M, Diao S, Rao Q, Zhang X, Xing H, Wang J.

Leuk Res. 2009 Sep;33(9):1243-8. doi: 10.1016/j.leukres.2009.02.016. Epub 2009 Mar 18.

PMID:
19299014
12.
13.

Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.

Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO.

Cell Death Dis. 2013 Feb 28;4:e516. doi: 10.1038/cddis.2013.39.

14.

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.

Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P, Haddach M, Michaux J, Nagasawa J, Schwaebe MK, Stefan E, Vialettes A, Whitten JP, Chen TK, Darjania L, Stansfield R, Bliesath J, Drygin D, Ho C, Omori M, Proffitt C, Streiner N, Rice WG, Ryckman DM, Anderes K.

Mol Cell Biochem. 2011 Oct;356(1-2):37-43. doi: 10.1007/s11010-011-0956-5. Epub 2011 Jul 14.

PMID:
21755459
15.

Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.

Manni S, Brancalion A, Tubi LQ, Colpo A, Pavan L, Cabrelle A, Ave E, Zaffino F, Di Maira G, Ruzzene M, Adami F, Zambello R, Pitari MR, Tassone P, Pinna LA, Gurrieri C, Semenzato G, Piazza F.

Clin Cancer Res. 2012 Apr 1;18(7):1888-900. doi: 10.1158/1078-0432.CCR-11-1789. Epub 2012 Feb 20.

16.

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.

Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MG, Lanza F, Secchiero P.

Haematologica. 2012 Nov;97(11):1722-30. doi: 10.3324/haematol.2012.062083. Epub 2012 Jun 11.

17.

Inhibition of CK2 enhances UV-triggered apoptotic cell death in lung cancer cell lines.

Zhao T, Jia H, Li L, Zhang G, Zhao M, Cheng Q, Zheng J, Li D.

Oncol Rep. 2013 Jul;30(1):377-84. doi: 10.3892/or.2013.2407. Epub 2013 Apr 18.

PMID:
23595577
18.

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.

Buontempo F, Orsini E, Lonetti A, Cappellini A, Chiarini F, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, Bertacchini J, Neri LM, McCubrey JA, Martelli AM.

Oncotarget. 2016 Jan 12;7(2):1323-40. doi: 10.18632/oncotarget.6361.

19.

Monitoring daunorubicin-induced alterations in protein expression in pancreas carcinoma cells by two-dimensional gel electrophoresis.

Möller A, Malerczyk C, Völker U, Stöppler H, Maser E.

Proteomics. 2002 Jun;2(6):697-705.

PMID:
12112851
20.

Synergistic anti-leukemic effects of CK2 inhibitors and pentabromobenzylisothioureas in vitro.

Koronkiewicz M, Chilmonczyk Z, Kazimierczuk Z.

Anticancer Res. 2013 Nov;33(11):4891-9.

PMID:
24222126

Supplemental Content

Support Center